Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single-Site, Double-Blind,Randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus or Intravenous Bolus Followed by Continuous Infusion Administration of ARC1779 Compared to Placebo in Healthy Volunteers

NCT00432770 is registered in ClinicalTrials.gov with Archemix Corp. as lead sponsor.

NCT NCT00432770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00432770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single-Site, Double-Blind,Randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus or Intravenous Bolus Followed by Continuous Infusion Administration of ARC1779 Compared to Placebo in Healthy Volunteers
Lead sponsor
Archemix Corp.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2006
Completion date
March 31, 2007
Enrollment
42
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thrombosis